BackBetter Therapeutics- Tradeable Rights - March 2021 Overview
Better Therapeutics Inc - Tradeable Rights - March 2021

Better Therapeutics- Tradeable Rights - March 2021 Return on Equity

Latest ROE for Better Therapeutics- Tradeable Rights - March 2021: 317.73% — see history and peer comparisons.

Get informed when a big investor buys or sells

+ Follow

ROE

317.73%

Return on Equity

317.73%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

Average ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

Better Therapeutics- Tradeable Rights - March 2021 (MCADR) FAQ

As of the most recent data, MCADR shows a ROE of 317.73%. That is above the sector sector average of -4.47%. Scroll down for historical charts and peer comparison views.

The its sector sector average ROE is about -4.47%. Better Therapeutics- Tradeable Rights - March 2021 is at 317.73%, which is higher that average. That is roughly 7210.7% above the sector mean. Use the comparison chart on this page to see how MCADR stacks up against individual peers as well.

Check the historical chart to see whether MCADR's ROE is trending up or down. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Better Therapeutics- Tradeable Rights - March 2021 with peers to see if the move is company-specific or sector-wide.

Besides this return on equity page, Stockcircle has Better Therapeutics- Tradeable Rights - March 2021's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect ROE (currently 317.73%) with ownership activity and broader fundamentals.